Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

KALA BIO, Inc.

CIK 1479419 KALA·Pharmaceutical Preparations · All EDGAR filings ↗

Progression

  1. Finance chief departure 8-K
  2. Material weakness 10-K +69d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Late filing Filing comparison

KALA BIO, Inc. told the SEC it could not file its quarterly report on time

Does not expect a significant change in results. Filed on the statutory due date.

(the “Company”) will not, without unreasonable effort and expense, be able to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 (the “Form 10-Q”) within the prescribed time period because the Company requires additional time to complete its analysis and disclosure regarding its liquidity and capital resources. The Company anticipates that it will file the Form 10-Q no later than the fifth calendar day following the prescribed filing date.
Evidence
Anticipates significant change
No
Days past due date
0
Other periodic reports filed
Yes
Routine
Yes
Severity
normal
Source
Form 12b-25 (notification of late filing)
Stated reason
(the “Company”) will not, without unreasonable effort and expense, be able to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 (the “Form 10-Q”) within the prescribed time period because the Company requires additional time to complete its analysis and disclosure regarding its liquidity and capital resources. The Company anticipates that it will file the Form 10-Q no later than the fifth calendar day following the prescribed filing date.
Why
The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗

Material weakness high Filing comparison

KALA BIO, Inc. reported a material weakness in internal control

Internal control reported effective → Material weakness in internal control

Based on the evaluation of our disclosure controls and procedures as of December 31, 2025, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were not effective. Management’s annual report on internal control over financial reporting Our management is responsible for establishing and maintaining adequate internal control over financial reporting for the company. Internal control over financial reporting is defined in Rule 13a-15(f) or…
Evidence
Current state
material_weakness
Current state label
Material weakness in internal control
Direction
newly reported
Prior filed
2025-03-31
Prior form
10-K
Prior state
effective
Prior state label
Internal control reported effective
Remediation stated
No
Severity
high
Source
Item 9A internal control conclusion, compared with the prior filing
Why
The company's conclusion on internal control over financial reporting changed: a material weakness was newly reported, or a previously reported one no longer appears.

Source filing ↗ Prior filing ↗

Late filing elevated Filing comparison

KALA BIO, Inc. filed its annual report late and said it expects a significant change in results

expects significant change in results Filed on the statutory due date. other reports also outstanding

(the “Company”) will not, without unreasonable effort and expense, be able to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “2025 Annual Report”) within the prescribed time period. The Company has undergone certain changes starting in November 2025, including significant director and officer turnover and a strategic transition in its business strategy. Additional time is needed for the Company to compile and analyze supporting documentation in order to complete its financial statement and disclosure preparation and review process to finalize the Form 10-K. The Company anticipates that it will file the Form 10-K no later than the fifteenth calendar day…
Evidence
Anticipates significant change
Yes
Days past due date
0
Other periodic reports filed
No
Routine
No
Severity
elevated
Source
Form 12b-25 (notification of late filing)
Stated reason
(the “Company”) will not, without unreasonable effort and expense, be able to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “2025 Annual Report”) within the prescribed time period. The Company has undergone certain changes starting in November 2025, including significant director and officer turnover and a strategic transition in its business strategy. Additional time is needed for the Company to compile and analyze supporting documentation in order to complete its financial statement and disclosure preparation and review process to finalize the Form 10-K. The Company anticipates that it will file the Form 10-K no later than the fifteenth calendar day…
Why
The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗

Finance chief departure Filing comparison

KALA BIO, Inc.'s Chief Financial Officer departed and a successor was named

Evidence
Interim only
No
Item code
5.02
Item title
Departure of Directors or Certain Officers
Role
Chief Financial Officer
Severity
normal
Source
SEC 8-K item code
Successor named
Yes
Why
The company's chief financial or accounting officer departed, disclosed under 8-K Item 5.02.

Source filing ↗